We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Oncology Update.
- Authors
Smart, Michael
- Abstract
This section offers news briefs related to oncology. The U.S. Food and Drug Administration (FDA) has approved a transdermal formulation of the 5-HT3 inhibitor Sancuso. The thrombopoiesis-stimulating agent romiplostim was approved by FDA for use in patients with chronic immune thrombocytopenic purpura (ITP) who have failed to respond sufficiently to standard irst-line therapies. A recent study has noted a correlation between heavy incense use and the development of respiratory squamous cell carcinomas.
- Subjects
UNITED States; ONCOLOGY; DRUG approval; DRUG development; UNITED States. Food &; Drug Administration
- Publication
Oncology Nursing Forum, 2009, Vol 36, Issue 1, p114
- ISSN
0190-535X
- Publication type
Article
- DOI
10.1188/09.ONF.114-116